Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

The research and intellectual property were part of the acquisition of assets from PharmaTher Holdings Ltd (CSE: PHRM) (OTCQB: PHRRF) in February 2021. The research study supported the Company’s PCT application (PCT/CA2021/050360), titled, “Use of Psilocybin in the Treatment of Neurological Brain Injury and Migraines.” The objective of the research study was to determine the protective effect of psilocybin in cellular and animal models of stroke. In the study, psilocybin reduced brain infarction and improved locomotor behavior in stroke rats; the protective mechanisms involve regulating BDNF expression. Read More